Recombinant Human TRAIL

Description

EnkiLife provides the Recombinant Human TRAIL protein,aslo know as Tumor Necrosis Factor Ligand Superfamily Member 10,Apo-2 Ligand,Apo-2L,TNF-Related Apoptosis-Inducing Ligand,Protein TRAIL,CD253,TNFSF10,APO2L,TRAIL, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human TNF-Related Apoptosis-Inducing Ligand is produced by our E.coli expression system and the target gene encoding Arg115-Gly281 is expressed.Accession:P50591. Expression Host:E.coli.Species:Human.Predicted Molecular Mass:19.5 KDa. Background:Human TNFSF10 is a type II transmembrane protein with an intracellular N-terminus and a ‘TNF homology domain’ (THD) at the extracellular C terminus. TNFSF10 can interact with several distinct receptors. Two of these receptors that belongs to TNFR superfamily, DR4 (TRAIL-R1) and DR5 (TRAIL-R2/TRICK2), are plasma membrane proteins containing intracellular death domains essential for activating apoptosis. TNFSF10 is promising for cancer therapy because it is cytotoxic and activates apoptosis in the majority of malignant cells, but not in normal cells.